NCT03166501View on ClinicalTrials.gov

NMDA Receptor Modulation for Hyperarousal in PTSD

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

November 12, 2019

Study Completion Date

November 14, 2019

Conditions
DepressionPost Traumatic Stress Disorder
Interventions
DRUG

Lanicemine

Three 60 min parenteral infusions over a 5 day period

DRUG

Placebo

Three 60 min parenteral infusions over a 5 day period

Trial Locations (1)

77030

Michael E. DeBakey VA Medical Center, Houston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Baylor College of Medicine

OTHER

NCT03166501 - NMDA Receptor Modulation for Hyperarousal in PTSD | Biotech Hunter | Biotech Hunter